Torasemid in the treatment of cardiovascular disease: the optimal use in conditions of comorbidity

The article reviews the current clinical data on the use of one of the modern pharmacological drugs torasemide (Diuver, Teva Pharmaceutical Industries Ltd., Israel) in the treatment of cardiovascular disease in conditions of comorbidity. Presents a comprehensive view of the problem identified and a...

Full description

Bibliographic Details
Main Authors: N G Poteshkina, A A Troshina
Format: Article
Language:Russian
Published: IP Morozov P.V. 2015-12-01
Series:Системные гипертензии
Subjects:
Online Access:https://syst-hypertension.ru/2075-082X/article/viewFile/29113/pdf
_version_ 1819106670941306880
author N G Poteshkina
A A Troshina
author_facet N G Poteshkina
A A Troshina
author_sort N G Poteshkina
collection DOAJ
description The article reviews the current clinical data on the use of one of the modern pharmacological drugs torasemide (Diuver, Teva Pharmaceutical Industries Ltd., Israel) in the treatment of cardiovascular disease in conditions of comorbidity. Presents a comprehensive view of the problem identified and a reasoned approach to the choice of diuretic therapy with clinico-pathophysiological substantiation of the use of a loop diuretic torasemid. Conceptually formed of a number of provisions on the application of one of the modern diuretic drugs in therapeutic practice in patients with arterial hypertension and heart failure.
first_indexed 2024-12-22T02:41:50Z
format Article
id doaj.art-092c95f22526419c8cbd178d85340f41
institution Directory Open Access Journal
issn 2075-082X
2542-2189
language Russian
last_indexed 2024-12-22T02:41:50Z
publishDate 2015-12-01
publisher IP Morozov P.V.
record_format Article
series Системные гипертензии
spelling doaj.art-092c95f22526419c8cbd178d85340f412022-12-21T18:41:37ZrusIP Morozov P.V.Системные гипертензии2075-082X2542-21892015-12-01124384126213Torasemid in the treatment of cardiovascular disease: the optimal use in conditions of comorbidityN G Poteshkina0A A Troshina1N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian FederationN.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation; City Clinical Hospital №52 of the Department of Health of MoscowThe article reviews the current clinical data on the use of one of the modern pharmacological drugs torasemide (Diuver, Teva Pharmaceutical Industries Ltd., Israel) in the treatment of cardiovascular disease in conditions of comorbidity. Presents a comprehensive view of the problem identified and a reasoned approach to the choice of diuretic therapy with clinico-pathophysiological substantiation of the use of a loop diuretic torasemid. Conceptually formed of a number of provisions on the application of one of the modern diuretic drugs in therapeutic practice in patients with arterial hypertension and heart failure.https://syst-hypertension.ru/2075-082X/article/viewFile/29113/pdfhypertensionheart failuretorasemiddiuver
spellingShingle N G Poteshkina
A A Troshina
Torasemid in the treatment of cardiovascular disease: the optimal use in conditions of comorbidity
Системные гипертензии
hypertension
heart failure
torasemid
diuver
title Torasemid in the treatment of cardiovascular disease: the optimal use in conditions of comorbidity
title_full Torasemid in the treatment of cardiovascular disease: the optimal use in conditions of comorbidity
title_fullStr Torasemid in the treatment of cardiovascular disease: the optimal use in conditions of comorbidity
title_full_unstemmed Torasemid in the treatment of cardiovascular disease: the optimal use in conditions of comorbidity
title_short Torasemid in the treatment of cardiovascular disease: the optimal use in conditions of comorbidity
title_sort torasemid in the treatment of cardiovascular disease the optimal use in conditions of comorbidity
topic hypertension
heart failure
torasemid
diuver
url https://syst-hypertension.ru/2075-082X/article/viewFile/29113/pdf
work_keys_str_mv AT ngpoteshkina torasemidinthetreatmentofcardiovasculardiseasetheoptimaluseinconditionsofcomorbidity
AT aatroshina torasemidinthetreatmentofcardiovasculardiseasetheoptimaluseinconditionsofcomorbidity